Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Effect of dapagliflozin on cardiac function in people with type 2 diabetes and albuminuria – A double blind randomized placebo-controlled crossover trial

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Silent atrial fibrillation detected by home-monitoring: Cardiovascular disease and stroke prevention in patients with diabetes

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Prediction of carotid intima-media thickness and its relation to cardiovascular events in persons with type 2 diabetes

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Peripheral, synaptic and central neuronal transmission is affected in type 1 diabetes

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Lipoprotein(a)and renal function decline, cardiovascular disease and mortality in type 2 diabetes and microalbuminuria

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Aims: Sodium glucose transport inhibitors (SGLT2i) can reduce risk of heart failure (HF) and cardiovascular death in people with type 2 diabetes (T2D) and existing cardiovascular disease. Our aim was to examine the effect of the SGLT2i dapagliflozin on cardiac function in people with T2D and albuminuria. Methods: A secondary analysis of a double-blind, randomized, cross-over study of 12 weeks treatment with dapagliflozin 10 mg versus placebo. Myocardial function was assessed by echocardiography and biomarkers of cardiac risk were measured. An exploratory diastolic composite of echocardiographic variables was computed. Results: Of the 36 participants completing the study 89% were male, mean age 64 ± 8 years, diabetes duration 16.4 ± 4.7 years and HbA1c 73 ± 15 mmol/mol (8.9 ± 1.4%), 30.6% had former cardiovascular events and 32% had macroalbuminuria. Mean left ventricular ejection fraction (LVEF) was 55.4% after placebo and 54.3% after dapagliflozin (p = 0.15), global longitudinal strain −16.1 vs. −15.9, (p = 0.64), E/e′ 7.6 vs. 7.6 (p = 0.082), and tissue Doppler velocity e′ 10.0 vs. 10.6 (p = 0.05). The composite score showed diastolic function improvement of 19.8% (p = 0.021). No other significant changes were observed. Conclusions: Dapagliflozin may have minor effects on diastolic function in people with T2D, albuminuria and preserved LVEF.

Original languageEnglish
Article number107590
JournalJournal of Diabetes and its Complications
Volume34
Issue number7
ISSN1056-8727
DOIs
Publication statusPublished - 1 Jul 2020

    Research areas

  • Albuminuria, Biomarkers, Cardiovascular disease, Echocardiography, SGLT2 inhibitor, Type 2 diabetes

ID: 59809639